You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

adult lymphocyte predominant Hodgkin lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Quality of Life in Adult and Pediatric Nodular

Recruiting
  • Nodular Lymphocyte-Predominant Hodgkin Lymphoma
    • Aurora, Colorado
    • +1 more
    Oct 27, 2023

    Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin

    Completed
    Has Results
    • Adult Lymphocyte Depletion Hodgkin Lymphoma
    • +5 more
    • gemcitabine hydrochloride
    • bendamustine hydrochloride
    • Atlanta, Georgia
    • +1 more
    Oct 21, 2021

    Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin

    Active, not recruiting
    • Adult Lymphocyte Depletion Hodgkin Lymphoma
    • +16 more
    • 6,8-bis(benzylthio)octanoic acid
    • bendamustine hydrochloride
    • Winston-Salem, North Carolina
    • +1 more
    Apr 8, 2022

    Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma, Refractory Nodular

    Not yet recruiting
    • Nodular Lymphocyte Predominant Hodgkin Lymphoma
    • +2 more
    • Biopsy
    • +9 more
    • (no location specified)
    Jun 1, 2023

    Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in

    Active, not recruiting
    • Accelerated Phase Chronic Myelogenous Leukemia
    • +125 more
    • tetanus-CMV fusion peptide vaccine
    • laboratory biomarker analysis
    • Duarte, California
      City of Hope Medical Center
    Feb 28, 2022

    Social and Genetic Factors on Outcomes in Adolescent and Young

    Not yet recruiting
    • Hodgkin Lymphoma
    • Non-Hodgkin Lymphoma
    • Biospecimen Collection
    • +2 more
    • (no location specified)
    Aug 18, 2023

    Non-hodgkin Lymphoma,B Cell Trial (CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection)

    Not yet recruiting
    • Non-hodgkin Lymphoma,B Cell
    • CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection
    • (no location specified)
    Feb 14, 2023

    Nodular Lymphocyte-Predominant Hodgkin's Lymphoma Trial in Cologne (Ibrutinib)

    Completed
    • Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
    • Cologne, Germany
      1st Department of Medicine, Cologne University Hospital
    Apr 6, 2021

    Leukemia, Stem Cell Transplantation Trial in Munich (FBTA05)

    Withdrawn
    • Leukemia
    • Stem Cell Transplantation
    • Munich, Bavaria, Germany
      3. Medizinische Klinik, Klinikum rechts der Isar der TU München
    Dec 5, 2022

    Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)

    Not yet recruiting
    • Relapsed or Refractory Non-Hodgkin's Lymphoma
    • Beijing, China
    • +3 more
    Jul 20, 2023

    Lymphoma Trial in Giessen (drug, other, procedure)

    Active, not recruiting
    • Lymphoma
    • Giessen, Germany
      Universitaetsklinikum Giessen-Marburg
    May 10, 2021

    Hodgkin Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma Trial in Rochester (drug, genetic, other)

    Withdrawn
    • Hodgkin Lymphoma
    • +4 more
    • Rochester, Minnesota
      Mayo Clinic
    Nov 28, 2022

    Hodgkin Lymphoma Trial in Latakia (First analysis: Lymphocyte count > or = 1500 cells per microlitre, second analysis: IPS < 3

    Recruiting
    • Hodgkin Lymphoma
    • First analysis: Lymphocyte count > or = 1500 cells per microlitre, second analysis: IPS < 3 and third analysis: Lymphocyte/Monocyte ratio > or = 2.9
    • First analysis: Lymphocyte count < 1500 cells per microlitre, second analysis: IPS > or = 3 and third analysis: Lymphocyte/Monocyte ratio < 2.9
    • Latakia, Syrian Arab Republic
      Tishreen University
    Feb 14, 2022

    Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)

    Not yet recruiting
    • Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
    • (no location specified)
    Mar 23, 2023

    Immunogenicity of COVID-19 Vaccinations in Autologous HSCT

    Not yet recruiting
    • COVID-19
    • +2 more
      • Cologne, NRW, Germany
        University Hospital of Cologne
      Oct 27, 2022

      Mature B-Cell Non-Hodgkin Lymphoma Trial (Obinutuzumab, Glofitamab, Rituximab)

      Not yet recruiting
      • Mature B-Cell Non-Hodgkin Lymphoma
      • (no location specified)
      Sep 6, 2022

      Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma Trial in San Antonio (WTX-330)

      Recruiting
      • Advanced or Metastatic Solid Tumors
      • Non-Hodgkin Lymphoma
      • San Antonio, Texas
        NEXT Oncology
      Jan 6, 2023

      B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine

      Not yet recruiting
      • B-cell Non Hodgkin Lymphoma
      • Chronic Lymphocytic Leukemia
      • Cyclophosphamide injection
      • +2 more
      • Charleston, South Carolina
        Hollings Cancer Center at Medical University of South Carolina
      Jan 18, 2023

      Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma Trial in Sacramento (biological, radiation, procedure, drug)

      Active, not recruiting
      • Refractory Non Hodgkin Lymphoma
      • Relapsed Non Hodgkin Lymphoma
      • rituximab
      • +7 more
      • Sacramento, California
        University of California Davis
      Nov 28, 2022

      NHL, NHL, Relapsed, Adult Trial in United States (CLN-978)

      Recruiting
      • NHL
      • NHL, Relapsed, Adult
      • Birmingham, Alabama
      • +4 more
      May 31, 2023

      Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,

      Active, not recruiting
      • Adult Grade III Lymphomatoid Granulomatosis
      • +23 more
      • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
      • +2 more
      • Duarte, California
        City of Hope Medical Center
      Jan 4, 2023

      Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia Trial in Tianjin (CC312)

      Recruiting
      • Non-hodgkin Lymphoma
      • +2 more
      • CC312
      • Tianjin, Tianjin, China
        InstituteHBDH
      Sep 12, 2023

      Lymphoma, Non-Hodgkin's, Adult Trial (SP-3164)

      Not yet recruiting
      • Lymphoma, Non-Hodgkin's, Adult
      • (no location specified)
      Aug 4, 2023

      Non Hodgkin Lymphoma Trial in Aurora (UCD19 CAR T Cells)

      Active, not recruiting
      • Non Hodgkin Lymphoma
      • UCD19 CAR T Cells
      • Aurora, Colorado
        University of Colorado Hospital
      Sep 1, 2022

      Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult Trial in Leon (Brentuximab Vedotin 50 MG

      Recruiting
      • Hodgkin Lymphoma
      • +2 more
      • Brentuximab Vedotin 50 MG [Adcetris]
      • Leon, Guanajuato, Mexico
        Hospital Regional Alta Especialidad Bajio
      Oct 24, 2022